Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Evaluar LAE102 en sujetos sanos y sujetos con sobrepeso y obesidad

10 de noviembre de 2026 actualizado por: Laekna Limited

Un estudio de fase I aleatorizado, doble ciego, controlado con placebo, de aumento de dosis única y múltiple para evaluar la seguridad, tolerabilidad y farmacocinética de LAE102 en sujetos sanos y sujetos con sobrepeso u obesidad

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of LAE102 injection in healthy and overweight/obese participants, and also evaluate the preliminary pharmacodynamic effect of multiple dose injections in overweight/obese participants.

Descripción general del estudio

Descripción detallada

Part A is a randomized, double-blinded, placebo-controlled, single ascending dose by Intravenous (IV) administration in 40 Healthy participants;

Part B is a randomized, double-blinded, placebo-controlled, single ascending dose by subcutaneous (SC) administration in 24 Healthy participants;

Part C is a randomized, double-blind, placebo-controlled, multiple dose ascending and expanding by subcutaneous (SC) administration in 60 overweight/obese participants.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

160

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Porcelana, 201203
        • Fudan Zhongshan Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 65 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Male or female and aged 18 to 65 years (inclusive) at the screening visit
  2. Male Body weight ≥ 50 kg, female Body weight ≥ 45 kg. For Part A&B, 18.5 ≤ BMI ≤ 28 kg/m². For part C, 26.0 ≤ BMI ≤ 40.0 kg/m²
  3. Negative for human immunodeficiency virus antibody (HIV-Ab).
  4. Female subjects with no childbearing potential or with childbearing potential which serum human chorionic gonadotropin (hCG) test must <5mIU/mL .
  5. Male subjects are not allowed to donate sperm during this trial.
  6. Voluntarily participate in the study and provide a signed and dated informed consent form.
  7. Willing to comply with the scheduled visits, study treatment, laboratory tests, and other study-related procedures and requirements as stipulated in the study protocol.

Exclusion Criteria:

  1. With clinically significant abnormalities in vital signs, physical examination, ECG or laboratory test results specified in the protocol.
  2. Allergy to the investigational drug or its excipients, or a history of severe allergy (including any food or drug allergies).
  3. Self-reported weight change is more than 5% in the previous 3 months prior to screening.
  4. Diagnosed with secondary overweight or obesity.
  5. Any clinically significant medical conditions and any diseases affecting the safety of the subject or the determination of study results.
  6. History of major diseases or physical conditions in the central nervous system, respiratory system, cardiovascular system, digestive system, blood system, endocrine system, musculoskeletal diseases, mental illness, urinary system, or tumors, or any existing acute diseases, or other diseases or physical conditions that may affect the study or pose an unacceptable risk to the subjects.
  7. Positive for hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCV-Ab), or syphilis spirochete antibody (TP-Ab).
  8. Known or suspected history of substance abuse or positive drug screening test.
  9. Alcohol abuse within 1 year before screening or positive alcohol breath test at baseline.
  10. Smoking more than 5 cigarettes per day within 3 months before screening, or unable to comply with the prohibition of smoking during the study period.
  11. Received any vaccine within 30 days prior to screening, or planned to receive any vaccine during the study period.
  12. Inability to ensure no use of any drugs, including prescription and non-prescription drugs (excluding paracetamol, ibuprofen, and topically applied eye/nasal drops and ointments with no systemic exposure risk), vitamins, supplements and herbal medicines, from 14 days before the initial administration (if the half-life of the drug used exceeds 14 days, then 5 half-lives shall apply) until the last visit period.
  13. Participated in any clinical trial and received an investigational medicine or medical device within 3 months prior to dosing of the investigational product.
  14. Underwent major surgery within 30 days before the initial administration or planned to undergo major surgery during the study period.
  15. Donated blood or experienced blood loss ≥400 mL within 3 months before screening or received a blood transfusion.
  16. Have special dietary requirements and cannot comply with a standardized diet.
  17. History of fainting or syncope.
  18. Dieting or receiving weight loss treatment within 30 days before the initial administration or experiencing major changes in lifestyle.
  19. Use of GLP-1 receptor agonists, or weight loss medications or systemic corticosteroids (oral or intravenous for more than 7 days), or psychiatric medications within 3 months prior to the initial administration. Applicable to part C.
  20. Regular engaged in muscle strength related exercise, applicable to part C.
  21. Other situation that the investigator considers not appropriate.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Part A LAE102 IV

Single dose LAE102 by IV administration

A single dose of LAE102 administered intravenously

Otros nombres:
  • LAE102 IV
Comparador de placebos: Part A placebo IV

Single dose placebo by IV administration

A single dose of placebo administered intravenously

Otros nombres:
  • Placebo iv
Experimental: Part B LAE102 SC

Single dose LAE102 by SC administration

Single dose of LAE102 administered subcutaneously

Otros nombres:
  • LAE102 SC
Comparador de placebos: Part B placebo SC

Single dose placebo by SC administration

single dose of placebo administered subcutaneously

Otros nombres:
  • Placebo sc
Experimental: Part C LAE102 SC

Multiple dose LAE102 by SC administration

Multiple dose of LAE102 administered subcutaneously

Otros nombres:
  • LAE102 SC
Comparador de placebos: Part C placebo SC

Multiple dose placebo by SC administration

Multiple dose of placebo administered subcutaneously

Otros nombres:
  • Placebo sc

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number & severity of participants with treatment-related adverse events as assessed by CTCAE V5.0
Periodo de tiempo: From Day 1 to Day 29 for single dose part. From Day 1 to Day 196 for multiple dose part

Findings on physical examination, ECG, vital signs, and reports of the laboratory results based on the CTCAE v5.0

From Day 1 to Day 29 for single dose part. From Day 1 to Day 196 for multiple dose part

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
characterize the peak of serum concentration (Cmax) of LAE102 injection in healthy subjects
Periodo de tiempo: From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.

For both intravenously guttae & subcutaneous injection, to evaluate the maximum observed serum concentration(Cmax)

From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
characterize the area under the serum concentration versus time curve (AUC) of LAE102 injection in healthy subjects
Periodo de tiempo: From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.

For both intravenously guttae & subcutaneous injection, to evaluate the area under the serum concentration versus time curve (AUC)

From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
evaluate the expression levels of Activin A in blood samples
Periodo de tiempo: From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.

The validated methodology was employed to assay serum levels of Activin A in biological samples.

From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
Incidence of positive Anti-drug antibody(ADA) after administration
Periodo de tiempo: pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.

Test ADA status in biological sample via validated methodology

pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Preliminary pharmacodynamic of total body weight for multiple dose part
Periodo de tiempo: From pre-dose to Day 168.

Changes and percentage changes in total body weight (kg) after administration

From pre-dose to Day 168.
Preliminary pharmacodynamic of lean mass for multiple dose part
Periodo de tiempo: From pre-dose to Day 168.

Changes and percentage changes in lean mass after administration

From pre-dose to Day 168.
Preliminary pharmacodynamic of fat mass for multiple dose part
Periodo de tiempo: From pre-dose to Day 168.

Changes and percentage changes in fat mass after administration

From pre-dose to Day 168.
Preliminary pharmacodynamic of thigh muscle volume for multiple dose part
Periodo de tiempo: From pre-dose to Day 168

Changes and percentage changes in thigh muscle volume after administration

From pre-dose to Day 168
Preliminary pharmacodynamic of bone mineral density(BMD) for multiple dose part
Periodo de tiempo: From pre-dose to Day 168

Changes and percentage changes in BMD after administration

From pre-dose to Day 168
BMI/waist circumference change and percentage.
Periodo de tiempo: From pre-dose to Day 29 forsingle dose. From pre-dose to Day 196 for multiple dose.

Assess the Body Mass Index (BMI)/waist circumference change and percentage.

From pre-dose to Day 29 forsingle dose. From pre-dose to Day 196 for multiple dose.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Xuening Li, Professor, Zhongshan hospital affiliated to Fundan University

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

25 de junio de 2024

Finalización primaria (Estimado)

30 de junio de 2027

Finalización del estudio (Estimado)

30 de diciembre de 2027

Fechas de registro del estudio

Enviado por primera vez

3 de junio de 2024

Primero enviado que cumplió con los criterios de control de calidad

2 de julio de 2024

Publicado por primera vez (Actual)

9 de julio de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir